Moderna Named a Top Employer by Science for Ninth Consecutive Year

CAMBRIDGE, MA / ACCESSWIRE / October 26, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as one of the top employers in the global biopharmaceutical industry in Science and Science Careers' 2023 Top Employers Survey for the ninth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with respect, and social responsibility.

"We are again honored to be recognized by Science as a top employer, with this year marking the ninth year in a row we have been named to this important list," said Stéphane Bancel, Chief Executive Officer of Moderna. "While Moderna has grown substantially since we were first recognized in 2015, our commitment to impacting the lives of patients and of our employees has never changed. We remain focused on being a company where people can do the best work of their lives."

Moderna's mRNA platform has demonstrated significant momentum across a variety of therapeutic areas in 2023, with clinical data across influenza, RSV, respiratory combinations, rare diseases and oncology. At its annual R&D Day in September, Moderna shared its ambitions to launch 15 products across oncology, respiratory, rare and latent diseases by 2028.

In 2023, Moderna has continued to invest in the power of digital technology, including through its immersive AI Academy for all employees and deployment of advanced AI capabilities that accelerate innovation, scale and value creation. Moderna also grew its U.S. footprint with a new technology hub in Seattle and a site in Marlborough, Massachusetts, that will support future manufacturing. As part of Moderna's ongoing commitment to social responsibility, the Company also marked the first anniversary of the Moderna Charitable Foundation and issued its second annual ESG Report. Moderna will host its second annual ESG Day on December 7.

"At Moderna, we are proud to give our people an opportunity to change the world and the tools to change medicine. We are energized every day by the possibilities of our platform and operate with a deep sense of responsibility to deliver the greatest possible impact to people through mRNA medicines," said Tracey Franklin, Chief Human Resources Officer of Moderna. "Our ongoing inclusion in Science's Top Employers list spotlights the talent and commitment of our people."

For over 20 years, Science has surveyed its readership to identify and celebrate the top 20 pharma and biotech companies with the best reputation as employers. The 2023 survey's findings were based on more than 6,800 completed surveys from readers of Science and other survey invitees, with responses from North America (59%), Europe (18%), Asia/Pacific Rim (16%) and other locations (7%). A vast majority (96%) of the respondents worked in biotechnology, biopharmaceutical, and pharmaceutical companies.

For the complete feature along with individual company rankings, please visit: https://www.science.org/content/article/making-happy-workplace-employees.

About Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio and integrated manufacturing facilities that allow for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past nine years. To learn more, visit www.modernatx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: Moderna's goal of launching 15 products by 2028. The forward-looking statements here are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ("SEC") and in subsequent filings made by the Company with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, the Company disclaims any intention or responsibility for updating or revising any forward-looking statements contained here in the event of new information, future developments or otherwise. These forward-looking statements are based on the Company's current expectations and speak only as of the date hereof.

Moderna Contacts

Media:
Kelly Cunningham
Associate Director, Communications & Media
617-899-7321
Kelly.Cunningham@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.